Zemdri (plazomicin; Achaogen) is now available for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis (in patients ≥18 years old) caused by the following susceptible microorganism(s): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae.

Zemdri, an aminoglycoside antibacterial, is a once-daily intravenous (IV) infusion that is designed to resist aminoglycoside-modifying enzymes. It possesses in vitro activity against extended spectrum beta-lactamase (ESBL)-producing, aminoglycoside-resistant, and carbapenem-resistant isolates. Dosing of Zemdri is based on patient weight and renal function; creatinine clearance should be assessed in all patients prior to initiating therapy and daily during therapy.

Related Articles

Zemdri carries a Boxed Warning describing reports of nephrotoxicity, ototoxicity, and neuromuscular blockade, as well as fetal harm if administered during pregnancy. As only limited clinical safety and efficacy data are available, Zemdri should be reserved for use in patients who have limited or no alternative treatment options.

Zemdri injection 500mg/10mL (50mg/mL) is supplied in single-dose, 10mL vials. The compatibility of Zemdri for administration with other drugs has not been established.

For more information visit Zemdri.com.